Actively Recruiting
New CSF Biomarkers for Alzheimer's Disease
Led by Central Hospital, Nancy, France · Updated on 2024-03-06
50000
Participants Needed
1
Research Sites
1955 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
CONDITIONS
Official Title
New CSF Biomarkers for Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lumbar puncture collected in usual practice in the context of dementia diagnosis
You will not qualify if you...
- Absence of consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU De Nancy
Nancy, Grand Est, France, 54500
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here